Crispr Therapeutics Ag (CRSP)

EBITDA Growth

-2.06%

TTM · Period ending:

CRSP logo

CRSP EBITDA Growth

Year-over-year change vs the same period a year earlier

Latest reported-2.06%
CRSP TTM EBITDA YoY % (-158.50% → -2.06%)
High-resolution chart · PNG

CRSP ebitda growth history

Trailing twelve months (TTM). Each value covers four complete reported quarters.

Crispr Therapeutics Ag EBITDA Growth — Trailing twelve months (TTM)
Period endingEBITDA Growth
-2.0593%
-50.6409%
-62.6314%
-114.5531%
-82.5833%
-85.695%
-162.3723%
36.0494%
39.5213%
61.2227%
79.1028%
47.3418%
32.5389%
-247.0822%
-256.5683%
-250.8176%
-229.8393%
188.7726%
215.8679%
287.8282%
15,931.1607%
-1,498.0059%
-770.8462%
-1,799.2241%
101.4275%
115.0209%
131.7338%
89.0402%
-140.4309%
-170.9374%
-163.1718%
-26.7242%
-7.2091%
8.8658%
6.6756%
-56.3632%
-66.2636%
-121.8894%
-158.503%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.